Carmichael Owen
Pennington Biomedical Research Center, Baton Rouge, LA, USA.
Adv Neurobiol. 2023;30:299-333. doi: 10.1007/978-3-031-21054-9_13.
Functional magnetic resonance imaging (fMRI) of the brain is a technology that holds great potential for increasing the efficiency of drug development for the central nervous system (CNS). In preclinical studies and both early- and late-phase human trials, fMRI has the potential to improve cross-species translation of drug effects, help to de-risk compounds early in development, and contribute to the portfolio of evidence for a compound's efficacy and mechanism of action. However, to date, the utilization of fMRI in the CNS drug development process has been limited. The purpose of this chapter is to explore this mismatch between potential and utilization. This chapter provides introductory material related to fMRI and drug development, describes what is required of fMRI measurements for them to be useful in a drug development setting, lists current capabilities of fMRI in this setting and challenges faced in its utilization, and ends with directions for future development of capabilities in this arena. This chapter is the 5-year update of material from a previously published workshop summary (Carmichael et al., Drug DiscovToday 23(2):333-348, 2018).
脑部功能磁共振成像(fMRI)是一项极具潜力的技术,有望提高中枢神经系统(CNS)药物研发的效率。在临床前研究以及早期和晚期人体试验中,fMRI有潜力改善药物效应的跨物种转化,有助于在研发早期降低化合物的风险,并为化合物的疗效和作用机制提供证据支持。然而,迄今为止,fMRI在CNS药物研发过程中的应用一直有限。本章旨在探讨这种潜力与应用之间的不匹配。本章提供了与fMRI和药物研发相关的入门材料,描述了fMRI测量在药物研发环境中发挥作用所需的条件,列出了fMRI在该环境中的当前能力以及应用中面临的挑战,并以该领域未来能力发展的方向作为结尾。本章是对先前发表的研讨会总结材料(Carmichael等人,《药物发现今天》23(2):333 - 348,2018年)的5年更新。